Studies on Hepatitis Viruses


Book Description

Studies on Hepatitis Viruses: Life Cycle, Structure, Functions, and Inhibition presents the latest on this systemic infection that predominantly affects the liver with inflammation that can be acute or chronic. Hepatitis viruses have been the subject of intense study in the last twenty years, with a wealth of information related to their lifecycle, structure, functions and inhibition being presented. This book compiles the most important developments and research, giving users a very useful guide on this evolving area of virology and medicinal chemistry. - Provides comprehensive, state-of-the-art coverage of hepatitis virus infections, the virus' lifecycle, and mechanisms of protease inhibition - Analyzes structure-activity relationships of inhibitors of viral hepatitis - Presents an in-depth view of the structure and function of viral hepatitis - Discusses classification, epidemiology, pathogenesis, natural history, clinical manifestations, diagnosis, complications, associated disorders and animal models




Eliminating the Public Health Problem of Hepatitis B and C in the United States


Book Description

Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.




Hepatitis B Virus


Book Description




Guidelines on Hepatitis B and C Testing


Book Description

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to receive the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviors and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination. These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.




Hepatitis and Liver Cancer


Book Description

The global epidemic of hepatitis B and C is a serious public health problem. Hepatitis B and C are the major causes of chronic liver disease and liver cancer in the world. In the next 10 years, 150,000 people in the United States will die from liver disease or liver cancer associated with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Today, between 800,000 and 1.4 million people in the United States have chronic hepatitis B and between 2.7 and 3.9 million have chronic hepatitis C. People most at risk for hepatitis B and C often are the least likely to have access to medical services. Reducing the rates of illness and death associated with these diseases will require greater awareness and knowledge among health care workers, improved identification of at-risk people, and improved access to medical care. Hepatitis B is a vaccine-preventable disease. Although federal public health officials recommend that all newborns, children, and at-risk adults receive the vaccine, about 46,000 new acute cases of the HBV infection emerge each year, including 1,000 in infants who acquire the infection during birth from their HBV-positive mothers. Unfortunately, there is no vaccine for hepatitis C, which is transmitted by direct exposure to infectious blood. Hepatitis and Liver Cancer identifies missed opportunities related to the prevention and control of HBV and HCV infections. The book presents ways to reduce the numbers of new HBV and HCV infections and the morbidity and mortality related to chronic viral hepatitis. It identifies priorities for research, policy, and action geared toward federal, state, and local public health officials, stakeholder, and advocacy groups and professional organizations.




Hepatitis B


Book Description

About 375 million people are infected with the hepatitis B virus. It has killed more people than AIDS and also causes millions of cases of liver cancer. The discovery of this deadly virus and the vaccine against it--a vaccine that is sharply decreasing the infection rate worldwide and is probably the first effective cancer vaccine--was one of the great triumphs of twentieth-century medicine. And it almost didn't happen. With wit and insight, this scientific memoir and story of discovery describes how Baruch Blumberg and a team of researchers found a virus they were not looking for and created a vaccine for a disease they previously knew little about--work that took the author around the world and won him the Nobel Prize. Blumberg and his collaborators were investigating relationships between gene distribution and disease susceptibility, research that was yielding interesting data but no real breakthroughs. Many viewed their work as more field trip than science. But, through decades of hard work and investigative twists and turns, their pursuit led to the hepatitis B antigen, the elusive virus itself, and, ultimately, the vaccine. As he takes the reader through the detective work that culminated in his incredible discovery, the author recounts with immediacy exciting moments in the lab and in the field--from a hair-raising flight to Africa to an unpleasant encounter with Alaskan sled dogs. The hepatitis B story is more than a fascinating chronicle of a major discovery. What Blumberg followed to the virus was a trail of remarkable "accidents" that happen when scientists seek answers to interesting questions. Those events, combined with the investigator's determined persistence, resulted in studies that generated a pharmaceutical industry, have far-flung public-health applications, and saved millions of lives.




Liver Disease in Children


Book Description

Completely revised new edition of the premier reference on pediatric liver disease. Liver Disease in Children, 3rd Edition provides authoritative coverage of every aspect of liver disease affecting infants, children, and adolescents. The book offers an integrated approach to the science and clinical practice of pediatric hepatology and charts the substantial progress in understanding and treating these diseases. Chapters are written by international experts and address the unique pathophysiology, manifestations, and management of these disorders in the pediatric population. The third edition has been thoroughly updated and features new contributions on liver development, cholestatic and autoimmune disorders, fatty liver disease, and inborn errors of metabolism. With the continued evolution of pediatric hepatology as a discipline, this text remains an essential reference for all physicians involved in the care of children with liver disease.




Dangerous Medicine


Book Description

The untold history of America’s mid-twentieth-century program of hepatitis infection research, its scientists’ aspirations, and the damage the project caused human subjects From 1942 through 1972, American biomedical researchers deliberately infected people with hepatitis. Government-sponsored researchers were attempting to discover the basic features of the disease and the viruses causing it, and to develop interventions that would quell recurring outbreaks. Drawing from extensive archival research and in-person interviews, Sydney Halpern traces the hepatitis program from its origins in World War II through its expansion during the initial Cold War years, to its demise in the early 1970s amid an outcry over research abuse. The subjects in hepatitis studies were members of stigmatized groups—conscientious objectors, prison inmates, the mentally ill, and developmentally disabled adults and children. The book reveals how researchers invoked military and scientific imperatives and the rhetoric of a common good to win support for the experiments and access to recruits. Halpern examines the participants’ long-term health consequences and raises troubling questions about hazardous human experiments aimed at controlling today’s epidemic diseases.







Hepatitis B Virus and Liver Disease


Book Description

This book provides a comprehensive, state-of-the art review of HBV infection and liver disease. It discusses new data on basic and translational medicine, including the viral life cycle, the immunopathogenesis of virus-induced chronic hepatitis, viral and host genetic factors affecting disease progression, and the mechanism of virus-induced hepatocarcinogenesis, as well as their potential applications in daily clinical practice. The clinical aspects of chronic HBV infection are examined in chapters on the global epidemiology, efficacy of HBV vaccination, natural history, co-infections with HCV, HDV or HIV, and management of special populations including children, pregnant women and patients undergoing immunosuppressive therapy. Further, it describes the advances and perspectives in the development of novel antiviral treatments as possible cures for HBV infection. The book is a valuable resource for medical students, physicians, and researchers who are interested in managem ent of patients with chronic HBV infection and investigation of HBV infection.